A method for analysis of yeast includes: receiving a microscopic image of yeast by a cloud server (2901), the microscopic image including a scaling pattern for determining a magnification; determining the magnification by the cloud server based on the scaling pattern (2902); and analyzing, by the cloud server, the microscopic image based on the magnification to obtain an analysis result (2903).

A proliferation inhibitor for canine cancer cells contains, as an active ingredient, 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isooxazol-3-yl)urea or CEP-32496, and a method for suppressing proliferation of canine cancer cells. The cancer cells are caused by BRAF gene mutation. The canine cancer is canine transitional epithelial cancer, canine prostate cancer, canine malignant melanoma, or canine peripheral schwannoma.

An object of the present invention is to provide a novel screening technique for selecting a useful pharmaceutical compound.

The present invention to solve the above problem is a method for screening active ingredients of a medicine, including the following step A, step B and/or step C, and step D. [step A] a step of administering a candidate substance to an animal (excluding human); [step B] a step of observing undifferentiated cells in the animal that has undergone step A; [step C] a step of observing differentiated cells in the animal that has undergone step A; and [step D] a step of selecting, as the active ingredient, a candidate substance that improves the amount of undifferentiated cells, or a candidate substance that improves the amount of differentiated cells or a candidate substance that improves a function of a tissue composed of differentiated cells, as compared with a case where the candidate substance is not administered.

An object of the present invention is to provide a novel screening technique for selecting a useful pharmaceutical compound.

The present invention to solve the above problem is a method for screening active ingredients of a medicine, including the following step A, step B and/or step C, and step D. [step A] a step of administering a candidate substance to an animal (excluding human); [step B] a step of observing undifferentiated cells in the animal that has undergone step A; [step C] a step of observing differentiated cells in the animal that has undergone step A; and [step D] a step of selecting, as the active ingredient, a candidate substance that improves the amount of undifferentiated cells, or a candidate substance that improves the amount of differentiated cells or a candidate substance that improves a function of a tissue composed of differentiated cells, as compared with a case where the candidate substance is not administered.

According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.

According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.

Cell counters and methods of their use are disclosed herein. The cell counters comprise a sample mounting system that includes a base comprising a mounted lower sample surface and a cover comprising a mounted upper sample surface; a bright-field light source incorporated in the cover; an objective lens mounted below the sample mounting system; optionally, a fluorescence excitation source in optical communication with the sample mounting system; and an imaging system in optical communication with the bright-field light source and the objective lens. The mounted sample surfaces are configured for repeated use, such that disposable sample cartridges are not needed.

Biological cells in a liquid suspension are counted in an automated cell counter that focuses an image of the suspension on a digital imaging sensor that contains at least 4,000,000 pixels each having an area of 2×2 μm or less and that images a field of view of at least 3 mm.sup.2. The sensor enables the counter to compress the optical components into an optical path of less than 20 cm in height when arranged vertically with no changes in direction of the optical path as a whole, and the entire instrument has a footprint of less than 300 cm.sup.2. Activation of the light source, automated focusing of the sensor image, and digital cell counting are all initiated by the simple insertion of the sample holder into the instrument. The suspension is placed in a sample chamber in the form of a slide that is shaped to ensure proper orientation of the slide in the cell counter.

Biological cells in a liquid suspension are counted in an automated cell counter that focuses an image of the suspension on a digital imaging sensor that contains at least 4,000,000 pixels each having an area of 2×2 μm or less and that images a field of view of at least 3 mm.sup.2. The sensor enables the counter to compress the optical components into an optical path of less than 20 cm in height when arranged vertically with no changes in direction of the optical path as a whole, and the entire instrument has a footprint of less than 300 cm.sup.2. Activation of the light source, automated focusing of the sensor image, and digital cell counting are all initiated by the simple insertion of the sample holder into the instrument. The suspension is placed in a sample chamber in the form of a slide that is shaped to ensure proper orientation of the slide in the cell counter.

A sphere-like cell aggregate according to one embodiment of the present invention comprises: a core part containing neural retina; and a covering part continuously or discontinuously covering at least a portion of a surface of the core part.